Risk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population
Carregando...
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2013
Editora
ELSEVIER SCIENCE INC
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
UROLOGY, v.82, n.1, p.182-188, 2013
Resumo
OBJECTIVE To evaluate the association of male lower urinary tract symptoms (LUTS) with metabolic syndrome (MetS) and androgenetic alopecia in a Latin American population. METHODS We enrolled 907 patients for prospective evaluation at a single institution. LUTS were evaluated with the International Prostate Symptom Score (IPSS). Subjects were evaluated with respect to hypertension, diabetes, dyslipidemia, previous cardiovascular events, body mass index (BMI), waist and hip circumference, and a laboratorial investigation including prostate-specific antigen (PSA), C-reactive protein (CRP), and gonadal steroids. Alopecia was classified according to the Norwood-Hamilton scale. RESULTS Mean patient age was 61.0 years; 57.5% of subjects had moderate/severe LUTS; MetS was present in 17.2% of subjects and 53.9% were classified as bald. Age, hypertension, diabetes, dyslipidemia, alopecia, previous cardiovascular event, and elevated waist-to-hip ratio (WHR) were associated with moderate/severe LUTS and with storage symptoms (P < .05). On multivariable analysis, age (odds ratio [OR] 2.30, 95% confidence interval [CI] 1.63-3.25), cardiovascular events (OR 1.73, 95% CI 1.07-2.78), and WHR (OR 1.65, 95% CI 1.13-2.40) were independent predictors for LUTS. For storage symptoms, age (OR 1.80, 95% CI 1.28-2.54), cardiovascular event (OR 2.07, 95% CI 1.27-3.39), WHR (OR 1.54, 95% CI 1.06-2.25), and MetS (OR 1.70, 95% CI 1.01-2.86) were independent risk factors. Age and cardiovascular event were the only independent predictors for voiding symptoms. CONCLUSION Components of the MetS were strongly associated with moderate and severe LUTS. WHR and cardiovascular events were independent predictors of voiding and storage symptoms, and MetS was an independent predictor of storage symptoms. Alopecia was not an independent predictor of LUTS. UROLOGY 82: 182-188, 2013. (C) 2013 Elsevier Inc.
Palavras-chave
Referências
- Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
- Arias-Santiago S, 2012, J AM ACAD DERMATOL, V66, P401, DOI 10.1016/j.jaad.2010.12.023
- Arias-Santiago S, 2010, J AM ACAD DERMATOL, V63, P420, DOI 10.1016/j.jaad.2009.10.018
- Azadzoi KM, 2007, J UROLOGY, V178, P710, DOI 10.1016/j.juro.2007.03.096
- Cellek S, 1999, BRIT J PHARMACOL, V128, P1804, DOI 10.1038/sj.bjp.0702981
- Chen WC, 2004, ARCH DERMATOL RES, V296, P245, DOI 10.1007/s00403-004-0514-z
- Gao Y, 2012, UROLOGY, V79, P194, DOI 10.1016/j.urology.2011.07.1399
- Guarrera M, 2009, Int J Trichology, V1, P120, DOI 10.4103/0974-7753.58554
- Gupta A, 2006, UROLOGY, V68, P1198, DOI 10.1016/j.urology.2006.09.034
- Hammarsten J, 2001, EUR UROL, V39, P151, DOI 10.1159/000052430
- Jin B, 1999, J CLIN ENDOCR METAB, V84, P3613, DOI 10.1210/jc.84.10.3613
- Kupelian V, 2013, J UROLOGY, V189, pS107, DOI 10.1016/j.juro.2012.11.026
- Lee RK, 2012, BJU INT, V110, P540, DOI 10.1111/j.1464-410X.2011.10819.x
- Montorsi F, 2011, BJU INT, V107, P1426, DOI 10.1111/j.1464-410X.2011.10129.x
- Neuhouser ML, 2004, UROLOGY, V64, P201, DOI 10.1016/j.urology.2004.04.025
- Nickel JC, 2011, BJU INT, V108, P388, DOI 10.1111/j.1464-410X.2011.10195.x
- NORWOOD OT, 1975, SOUTHERN MED J, V68, P1359
- Oh BR, 1998, UROLOGY, V51, P744, DOI 10.1016/S0090-4295(98)00108-3
- Ohgaki K, 2011, UROLOGY, V77, P1432, DOI 10.1016/j.urology.2010.12.024
- Rohrmann S, 2005, INT J OBESITY, V29, P310, DOI 10.1038/sj.ijo.0802881
- Rossi A, 2011, DERMATOL THER, V24, P455, DOI 10.1111/j.1529-8019.2011.01441.x
- Severi G, 2003, BRIT J DERMATOL, V149, P1207, DOI 10.1111/j.1365-2133.2003.05565.x
- Shenfeld OZ, 2005, UROLOGY, V65, P181, DOI 10.1016/j.urology.2004.08.055
- Su LH, 2010, BRIT J DERMATOL, V163, P371, DOI 10.1111/j.1365-2133.2010.09816.x
- Temml C, 2009, UROLOGY, V73, P544, DOI 10.1016/j.urology.2008.10.027
- Vignozzi L, 2012, J ENDOCRINOL, V212, P71, DOI 10.1530/JOE-11-0289
- Yang TK, 2012, UROLOGY, V80, P1093, DOI 10.1016/j.urology.2012.08.002
- Yip L, 2011, AUSTRALAS J DERMATOL, V52, P81, DOI 10.1111/j.1440-0960.2011.00745.x
- Zhu YS, 2009, ANN NY ACAD SCI, V1155, P43, DOI 10.1111/j.1749-6632.2009.04115.x